Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • Reporting Rate Calculator
  • Signal Detection
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Myocarditis
  • Guillain-Barré
  • Allergic Reactions
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. Influenza, Seasonal (Flulaval Quadrivalent)
  4. Sensory loss
Influenza, Seasonal (Flulaval Quadrivalent)×Sensory loss

Sensory loss Reports for Influenza, Seasonal (Flulaval Quadrivalent)

#348 most reported symptom for this vaccine

64
Reports
1
Deaths
31
Hospitalizations
1.56
Mortality Rate
%
48.4
Hosp. Rate
%

Sensory loss and Influenza, Seasonal (Flulaval Quadrivalent)

Sensory loss has been reported 64 times in association with Influenza, Seasonal (Flulaval Quadrivalent) vaccination in VAERS. This represents 0.1% of all 52,111 reports for this vaccine.

Among these reports, 1 mentioned death (1.56%) and 31 involved hospitalization (48.4%).

Sensory loss is the #348 most frequently reported symptom for Influenza, Seasonal (Flulaval Quadrivalent) out of 2354 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 64 reports of Sensory loss after Influenza, Seasonal (Flulaval Quadrivalent) vaccination may seem alarming, but context is critical.

The mortality rate of 1.56% warrants monitoring, though VAERS deaths represent temporal associations, not confirmed causal links.

Important Context

•Association, not causation: These reports show Sensory loss occurred after vaccination, not that the vaccine caused it.
•Background rates: Sensory loss may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Sinus congestion64 reportsAngioedema64 reportsWalking aid user63 reportsDry mouth63 reports

Quick Facts

Reports:64
Deaths:1
Hospitalizations:31
% of Vaccine:0.1%
Rank:#348 of 2354

Related Pages

Influenza, Seasonal (Flulaval Quadrivalent) OverviewSensory loss (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.